| |
Three patients with inoperable pancreatic cancer showed stable disease following an experimental genetically engineered adenovirus injection in a University of Minnesota Phase I trial, with one participant achieving 15 months of disease control. The treatment works by entering cancer cells, replicating within them, and potentially making tumors more recognizable to the immune system. However, researchers emphasize these are preliminary findings from a small safety and dosing study, not proof of survival benefit or cure, and larger clinical comparisons are needed to establish the treatment's true effectiveness.
Read Full Article →
← More Science news